AVEO Pharmaceuticals, Inc.

Then gently stand by. Your conference call will begin shortly. We thank you for your patience. Please remain online. Your conference call will begin soon. Thank you.

Good morning and welcome to Aveo Oncology First Quarter 2022 Financial Results Conference Call. During the presentation, all participants will be in a listen-only mode. Afterwards, we will conduct a question and answer session. At that time, if you have a question, please press the 1 followed by the 4 on your telephone. If at any time during the conference you need to reach an operator, please press star 0. As a reminder, today's conference is being recorded. I will now turn the call over to Hans Visthum of LifeSci Advisors. Please go ahead, sir.

Good afternoon, and thank you all for joining us on today's call to discuss Aveo's first quarter 2022 financial results conference call. I'm joined today by Michael Bailey, Chief Executive Officer, Mike Ferraresso, Chief Commercial Officer, Eric Lucera, Chief Financial Officer, and Jeb Liddell, Chief Operating Officer. Before we begin today's call, let me remind you that during this discussion, we will be making forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to important risks and uncertainties, including those that are detailed in today's press release and in the risk factor section of our most recent report on Form 10-Q, which is on file with the SEC. that may cause actual results to differ materially from those results expressed in such statements. Furthermore, we caution you that these forward-looking statements represent our views only as of today, and we do not assume any obligation to update these statements, whether as a result of new information, future events, or otherwise, except as required by law. With that, I will now turn the call over to Aveo's President and Chief Executive Officer, Michael Bailey. Michael?